Electromagnetic detection of HIV DNA in the blood of AIDS patients treated by antiretroviral therapy

  • Luc Montagnier
  • Jamal Aïssa
  • Claude Lavallée
  • Mireille Mbamy
  • Joseph Varon
  • Henri Chenal
Article

Abstract

Electromagnetic signals of low frequency have been shown to be durably produced in aqueous dilutions of the Human Imunodeficiency Virus DNA. In vivo, HIV DNA signals are detected only in patients previously treated by antiretroviral therapy and having no detectable viral RNA copies in their blood. We suggest that the treatment of AIDS patients pushes the virus towards a new mode of replication implying only DNA, thus forming a reservoir insensitive to retroviral inhibitors. Implications for new approaches aimed at eradicating HIV infection are discussed.

Key words

HIV DNA antiretroviral therapy HIV reservoir HIV LTR detection HIV DNA with erythrocyte fraction 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Douglas, D.R., David, M.M., Martin, D., Warner, C.G., Daria, H., Roger, P. 2009. The challenge of finding a cure for HIV infection. Science 323, 1304–1307.CrossRefGoogle Scholar
  2. [2]
    Meyerhans, A., Breinig, T., Vartanian, J.-P., Wain-Hobson, S. 2003. Forms and function of intracellular HIV DNA. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, LA-UR number 04-7420.Google Scholar
  3. [3]
    Montagnier, L., Aïssa, J., Ferris, S., Montagnier, J.L, Lavallée, C. 2009. Electromagnetic signals are produced by aqueous nanostructures. Interdiscip Sci Comput Life Sci 1, 81–90.CrossRefGoogle Scholar
  4. [4]
    Montagnier, L., Lavallée, C. 2007. Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing. US Patent No WO 2007/011367 A2.Google Scholar
  5. [5]
    Peden, K., Emerman, M., Montagnier, L. 1991. Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology 185, 661–672.CrossRefPubMedGoogle Scholar
  6. [6]
    Sharkey, M.E., Teo, I., Greenough, T., Sharova, N., Luzuriaga, K., Sullivan, J.L., Bucy, R.P., Kostrikis, L.G., Haase, A., Veryard, C., Davaro, R.E., Cheeseman, S.H., Daly, J.S., Bova, C., Ellison, R.T. 3rd, Mady, B., Lai, K.K., Moyle, G., Nelson, M., Gazzard, B., Shaunak, S., Stevenson, M. 2000. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med 6, 76–81.CrossRefPubMedGoogle Scholar
  7. [7]
    Zuniga, J.M., Whiteside, A., Ghaziani, A., Bartlett, J.G. 2008. A decade of HAART. In: The development and global impact of highly active antiretroviral therapy. Oxford University Press.Google Scholar

Copyright information

© International Association of Scientists in the Interdisciplinary Areas and Springer Berlin Heidelberg 2009

Authors and Affiliations

  • Luc Montagnier
    • 1
    • 2
  • Jamal Aïssa
    • 2
  • Claude Lavallée
    • 1
  • Mireille Mbamy
    • 3
  • Joseph Varon
    • 4
  • Henri Chenal
    • 3
  1. 1.World Foundation for AIDS research and Prevention (UNESCO)ParisFrance
  2. 2.Nanectis BiotechnologiesJouy-en-JosasFrance
  3. 3.CIRBA Centre Intégré de Recherches Biocliniques d’Abidjan18 AbidjanIvory Coast
  4. 4.The University of Texas Health Science CenterHoustonUSA

Personalised recommendations